Merck Q1 Revenue Beats, Shares Up 4%

Merck reported Q1 2026 revenue of $16.29 bn, up 5% YoY and beating the $15.89 bn estimate.
Adjusted loss per share narrowed to $1.28, surpassing consensus loss of $1.48, despite a $3.62 per share acquisition charge.
Oncology product KEYTRUDA sales hit $8.03 bn, up 12% YoY, while WINREVAIR surged 88% to $525 m.
Merck raised full‑year 2026 revenue guidance to $65.8‑$67.0 bn and adjusted EPS outlook to $5.04‑$5.16, with midpoint $5.10.